377 related articles for article (PubMed ID: 30859662)
21. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
[TBL] [Abstract][Full Text] [Related]
22. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Sun Y; Hu J; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Transpl Infect Dis; 2021 Aug; 23(4):e13611. PubMed ID: 33825274
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center.
Linke C; Tragiannidis A; Ahlmann M; Fröhlich B; Wältermann M; Burkhardt B; Rossig C; Groll AH
Mycoses; 2019 Oct; 62(10):954-960. PubMed ID: 31332851
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
26. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
[TBL] [Abstract][Full Text] [Related]
27. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies.
Deng Q; Lv HR; Lin XM; Zhao MF; Geng L; Li YM
Curr Med Res Opin; 2018 Jul; 34(7):1209-1216. PubMed ID: 28956459
[TBL] [Abstract][Full Text] [Related]
28. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
30. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
[TBL] [Abstract][Full Text] [Related]
31. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.
Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M
Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of invasive fungal disease in haematologic patients.
Souza L; Nouér SA; Morales H; Simões B; Solza C; Queiroz-Telles F; Nucci M
Mycoses; 2021 Mar; 64(3):252-256. PubMed ID: 33141969
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China.
Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
Clin Ther; 2017 Sep; 39(9):1758-1768. PubMed ID: 28756883
[TBL] [Abstract][Full Text] [Related]
34. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
35. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
36. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Takagi S; Araoka H; Uchida N; Uchida Y; Kaji D; Ota H; Nishida A; Ishiwata K; Tsuji M; Yamamoto H; Ito T; Matsuno N; Yamamoto G; Asano-Mori Y; Hayashi M; Izutsu K; Masuoka K; Wake A; Makino S; Yoneyama A; Taniguchi S
Int J Hematol; 2014; 99(5):652-8. PubMed ID: 24664791
[TBL] [Abstract][Full Text] [Related]
37. Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants.
Azik FM; Tezer H; Ozkaya-Parlakay A; Aksu T; Bayram C; Fettah A; Tavil B; Tunç B
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e19-22. PubMed ID: 25522351
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and Safety of Low-dose Amphotericin B in Different Antifungal Strategies for Treatment of Invasive Fungal Disease in Patients with Hematological Malignancies].
Yang L; Jin XS; Li JH; Liu J; Guan W; Gao HH; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):221-225. PubMed ID: 28245405
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
40. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
